Oxford Immunotec Announces Update in Patent Infringement Litigation
(Thomson Reuters ONE) -
OXFORD, United Kingdom and MARLBOROUGH, Mass., Sept. 27, 2017 (GLOBE NEWSWIRE)
-- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics
company focused on developing and commercializing proprietary tests for the
management of underserved immune-regulated conditions, today announced a
decision of the U.S. District Court for the District of Massachusetts in the
Company's patent infringement lawsuit against Qiagen, Inc., Quest Diagnostics,
Inc. and Laboratory Corporation of America Holdings on the Company's motion
seeking to enjoin Qiagen from promoting its QuantiFERON-TB Gold Plus (QFT-Plus)
product to new customers in the U.S. Although the court denied the Company's
motion because it believed the Company was not likely to suffer irreparable harm
from QFT-Plus during the few months remaining before trial, it found that the
Company was likely to prevail on the merits of its claims at trial and that
Qiagen had not shown that it was likely to succeed on its subject matter, prior
art or non-infringement objections. The court further noted that if the Company
"prevails at trial, it is likely that the infringing aspects of the QFT Plus
will be permanently enjoined."
"While we are disappointed that the court did not grant a preliminary injunction
prohibiting the sale of Qiagen's QFT-Plus product in the U.S. before trial, we
are encouraged by the court's rulings on the issues of validity and
obviousness," said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford
Immunotec. "We continue to look forward to the further defense of our patents at
the upcoming trial in January."
About Oxford Immunotec
Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused
on developing and commercializing proprietary tests for the management of
underserved immune-regulated conditions. The Company's first product is the T-
SPOT®.TB test, which is used to test for tuberculosis infection. The T-
SPOT.TB test has been approved for sale in over 50 countries, including the
United States, where it has received pre-market approval from the Food and Drug
Administration, Europe, where it has obtained a CE mark, as well as Japan and
China. The Company's second product line is a range of assays for tick-borne
diseases, such as Lyme disease, obtained through the acquisitions of Imugen and
Immunetics. Also obtained through the acquisitions is the Company's third
product line focused on screening for Babesia in donated blood, for which the
Company is currently seeking FDA licensure. The T-SPOT.CMV test and the T-
SPOT.PRT test are pipeline products as part of the Company's fourth intended
product line focused on the transplantation market. In addition to these four
product lines, the Company has additional active development programs in other
immune-regulated conditions. The Company is headquartered near Oxford, U.K. and
in Marlborough, Mass. Additional information can be found
at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.
Immunetics is a trademark of Immunetics, Inc.
CONTACT:
For Media and Investor Inquiries:
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
kkoski(at)oxfordimmunotec.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 27.09.2017 - 15:33 Uhr
Sprache: Deutsch
News-ID 561557
Anzahl Zeichen: 4034
contact information:
Town:
Oxfordshire
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 283 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Oxford Immunotec Announces Update in Patent Infringement Litigation"
steht unter der journalistisch-redaktionellen Verantwortung von
Oxford Immunotec (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
